A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
The LumiSystem is a detection tool that uses fluorescence imaging technology during lumpectomy, offering a more complete resection vs other detection systems that evaluate tissue after surgical ...
Patients diagnosed with more advanced breast cancer are more likely to have cardiovascular disease, a large study suggests.
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...
Australian researchers achieve a breakthrough in improving breast cancer cure rates, offering new hope for patients worldwide ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, “Sustained Release Compositions of Endoxifen.” The 31 claims of this new patent are ...
Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.
Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the U.S. commercial availability and first commercial use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback